Pharmaceutical Market Research Company in USA

BioNixus is a specialist pharmaceutical and healthcare market research company serving the US market. We help launch, access, and medical teams translate FDA approval pathways, CMS reimbursement dynamics, PBM formulary strategies, and physician decision behavior into actionable US market evidence — with IRB-compliant execution across oncology, immunology, cardiovascular, rare disease, and other therapy areas.

For broader healthcare research context, see our healthcare market research hub and the US healthcare market research overview.

Best pharmaceutical market research company in USA

BioNixus is a pharmaceutical market research company in the USA, specialising in FDA-aligned HCP surveys, KOL mapping, PBM and CMS payer research, and IRA drug negotiation impact studies for pharmaceutical and biotech clients.

FDA and CMS Market Access AlignmentPrograms designed around FDA approval pathways and CMS reimbursement dynamics — NDA, BLA, Medicare Part B/D coverage, and IRA drug negotiation context built into study design from the start.
PBM and Payer Research DepthDeep intelligence on PBM formulary committees, Medicare Part D coverage policies, and commercial insurance formulary dynamics — the access gatekeepers that determine real US market penetration.
US KOL and HCP NetworkVerified physician recruitment across major US academic medical centres, NCI cancer centres, integrated delivery networks, and community practice networks across all US regions.
IRB-Compliant ExecutionResearch designed and executed in compliance with US IRB/OHRP requirements and HIPAA/HITECH data privacy standards — ensuring findings can support US regulatory and access submissions.

BioNixus delivers primary pharmaceutical market research in the US with IRB-compliant methodologies, FDA/CMS/PBM-aligned study design, and KOL access across major US academic medical centres.

Why BioNixus for US pharmaceutical market research

FDA and IRA context built in

Every study is designed with FDA approval pathway context and IRA Medicare negotiation dynamics — essential for commercial strategy in 2026 and beyond.

PBM and payer access intelligence

Deep in-house expertise across PBM formulary committees, Medicare Part B/D, Medicaid managed care, and commercial insurance dynamics.

US academic medical centre network

Verified HCP recruitment across Mayo Clinic, Cleveland Clinic, Johns Hopkins, MSKCC, UCSF, and leading community IDN networks.

IRB-compliant protocols

US research designed and executed under 45 CFR Part 46 / Common Rule and HIPAA/HITECH standards — ensuring findings meet regulatory and compliance requirements.

Therapy area specialization

Specialist expertise across oncology, immunology, cardiovascular, diabetes/metabolic (GLP-1/IRA dynamics), rare disease, and gene therapy.

Global benchmarking ready

US modules connect to comparable studies across the UK, EU5, Brazil, Saudi Arabia, and UAE — for clients managing global portfolio decisions from one research partner.

US pharmaceutical market access pathway

US pharmaceutical market research must follow how products move from FDA approval through PBM formulary listing, Medicare/Medicaid coverage decisions, GPO contracting, and hospital IDN adoption — not a single generic access model.

1. FDA approval (NDA / BLA)
NDA (New Drug Application) for small molecules; BLA (Biologics License Application) for biologics. Priority Review, Breakthrough Therapy, Accelerated Approval, and Fast Track designations reduce timelines for qualifying products. FDA approval grants market authorisation but not commercial access.
USA healthcare market report
2. PBM formulary negotiations
The three dominant PBMs — UnitedHealth/Optum Rx, CVS/Caremark, Express Scripts/Cigna — collectively manage formulary placement for the majority of US commercial and Medicare Part D lives. Formulary tier and co-pay dynamics determine real-world commercial uptake. BioNixus conducts PBM formulary research and payer landscape studies to support access strategy.
US PBM payer research
3. CMS coverage (Medicare Part B / Part D)
Medicare Part B covers physician-administered drugs using ASP + 6% reimbursement. Part D covers pharmacy-dispensed outpatient drugs through PBM-managed plans. IRA Medicare price negotiation (effective 2026) has created MFPs for high-spend products — reshaping commercial strategy for the first-negotiated cohort.
US healthcare market research
4. GPO and IDN hospital contracting
Hospital Group Purchasing Organizations (Premier, Vizient, HealthTrust) negotiate pricing for the majority of US hospital systems. Integrated Delivery Networks (IDNs) with pharmacy and therapeutics (P&T) committees make formulary decisions independently. BioNixus conducts hospital P&T committee research and GPO contracting intelligence.
Top healthcare MR companies USA
5. ICER and HTA context
ICER (Institute for Clinical and Economic Review) publishes independent cost-effectiveness assessments that carry significant payer and media influence despite having no statutory authority. ICER assessments increasingly shape PBM formulary strategy and commercial rebate negotiations. BioNixus conducts pre-ICER evidence strategy research and post-ICER payer impact studies.
Top market research companies USA

US stakeholder coverage

Stakeholder	Research focus
Physicians and specialists	Prescribing behavior, treatment algorithms, adoption drivers and barriers, unmet need assessment, therapy sequencing
KOLs and academic physicians	KOL identification and mapping at major AMCs (Mayo, Cleveland Clinic, MSKCC, Johns Hopkins, UCSF), advisory board research, publication influence analysis
PBM medical directors	Formulary positioning preferences, coverage criteria, rebate threshold intelligence, IRA negotiation impact
Medicare and payer medical directors	Coverage policies, prior authorization criteria, step therapy requirements, ICER evidence weight
Hospital P&T committee members	Formulary listing drivers, cost-effectiveness evidence needs, GPO contract dynamics, biosimilar substitution policies
Nurses and pharmacists	Administration experience, adherence support, patient counselling practices, formulary substitution behavior
Patients and caregivers	Disease journey, quality of life, adherence barriers, patient assistance program awareness — HIPAA-compliant, IRB-approved

Why the US pharmaceutical market is unique

The United States is the world's largest pharmaceutical market — estimated at USD 590–640 billion in 2026 and representing approximately 45% of global pharmaceutical sales. No other market combines FDA's science-based approval standards, a multi-payer system with PBM intermediaries, IRA-driven Medicare price negotiation, and GPO-mediated hospital contracting in a single commercial environment.

Market access in the US is uniquely decentralized: FDA approval does not guarantee coverage or commercial uptake. Commercial outcomes depend on PBM formulary placement, Medicare Part B/D coverage decisions, Medicaid managed care contracts, and hospital P&T committee listings — each with distinct evidence requirements and negotiation dynamics. Effective pharmaceutical market research must map all these access layers rather than treating US approval as equivalent to market access.

The IRA's Medicare price negotiation mechanism (effective 2026) has added a new layer of strategic complexity for products with significant Medicare exposure. BioNixus builds US research programs that answer decision-critical questions: where physician demand concentrates by specialty and geography, which payer and PBM dynamics determine formulary access, how IRA negotiated prices affect commercial strategy, and what evidence payer committees and ICER assessors will require.

US pharmaceutical research services

HCP and physician surveys

IRB-compliant quantitative surveys and qualitative in-depth interviews with US physicians, oncologists, cardiologists, and specialists across academic medical centres and community practices.

KOL mapping and advisory boards

Key opinion leader identification and influence mapping across US AMCs, NCI-designated cancer centres, and specialty society advisory structures — by therapy area and commercial priority.

Payer and PBM research

In-depth interviews with PBM medical directors, Medicare plan medical directors, and commercial insurer pharmacy directors — covering formulary positioning, coverage criteria, and IRA impact intelligence.

HEOR and market access evidence

Health economics and outcomes research, patient-reported outcome (PRO) development, cost-effectiveness evidence strategy, and pre-ICER assessment research to support US market access dossiers.

For broader research context, see our market research services hub, healthcare market research USA, and USA healthcare market report.

US case study patterns we solve

Case Pattern 1: PBM formulary positioning for an IRA-exposed oncology product

Challenge: A commercial team needed to understand PBM formulary positioning dynamics for a product subject to Medicare IRA negotiation. Solution: BioNixus conducted PBM medical director and formulary committee interviews alongside oncologist prescribing research. Result: Refined negotiation strategy and commercial positioning ahead of MFP announcement.

Typical impact range: 15–25% improvement in formulary access outcomes post-negotiation.

Case Pattern 2: KOL mapping for a specialty biologic launch at MSKCC and Mayo Clinic

Challenge: A biotech team lacked visibility on actual prescribing influence versus publication prominence at key AMCs. Solution: BioNixus mapped real-world KOL influence at MSKCC, Mayo Clinic, and Cleveland Clinic using network analysis and verified physician interviews. Result: Sharper MSL territory prioritization and advisory board composition.

Typical impact range: 20–30% improvement in MSL engagement efficiency.

Case Pattern 3: Pre-ICER evidence strategy for a cardiovascular therapy

Challenge: A global pharma team needed to understand which cost-effectiveness evidence would carry most weight with PBMs and Medicare payers before an ICER assessment. Solution: BioNixus conducted payer interviews mapping ICER evidence weight alongside commercial team intelligence. Result: Prioritized HEOR investment and pre-positioned evidence narrative.

Typical impact range: 18–28% reduction in late-stage evidence rework.

Regulatory context: FDA, CMS, IRA, and HIPAA

US pharmaceutical market research quality depends on aligning federal regulatory and payer context with evidence design from the start. FDA's evidence standards, CMS coverage policies, IRA negotiation mechanics, IRB ethics requirements, and HIPAA data privacy rules form the compliance architecture within which all effective US primary research must operate.

BioNixus outputs are decision-ready and compliance-ready: stakeholder evidence combined with US market structure analysis so commercial, access, and medical affairs teams have findings that reflect what US physicians, payers, and formulary committees actually do — not imported non-US templates applied to the American market.

Related US healthcare research resources

Healthcare market research USA USA healthcare market report Top healthcare market research companies USA Top market research companies USA Pharmaceutical market research UAE Pharmaceutical market research Saudi Arabia

US pharmaceutical market FAQs

Who is the best pharmaceutical market research company in the USA?

For pharmaceutical and life-sciences decisions in the US market, BioNixus is a leading specialist: FDA-aligned study design, PBM and CMS payer context, HCP and KOL recruitment across major US academic medical centres, and outputs built for launch, market access, and lifecycle management teams.

What is pharmaceutical market research in the USA?

Pharmaceutical market research in the USA is evidence generation for drug launch, market access, and lifecycle decisions across FDA, CMS, and PBM contexts. BioNixus focuses on physician behavior, payer and formulary dynamics, and institution-level adoption so commercial and access teams can prioritize US market execution across oncology, immunology, cardiovascular, and rare disease therapy areas.

How does the IRA (Inflation Reduction Act) affect US pharmaceutical market research?

The Inflation Reduction Act of 2022 introduced Medicare drug price negotiation for the highest-spend products — 10 drugs from January 2026, expanding annually. This has significantly changed commercial strategy for products with Medicare exposure, particularly in cardiovascular, diabetes, and oncology. BioNixus conducts IRA impact research: payer and PBM formulary strategy studies, Medicare Part D beneficiary research, and commercial team intelligence on how MFPs (Maximum Fair Prices) affect market access dynamics.

What types of US payer and formulary research does BioNixus conduct?

BioNixus covers all major US payer segments: commercial insurance (employer-sponsored, ACA marketplace), Medicare Part B (physician-administered) and Part D (pharmacy-dispensed), Medicaid managed care, and PBM formulary committees (UnitedHealth/Optum, CVS/Caremark, Express Scripts/Cigna). Research includes in-depth interviews with medical directors and pharmacy benefit managers, formulary listing studies, PBM negotiation intelligence, and willingness-to-pay research.

Can BioNixus conduct IRB-compliant HCP research in the USA?

Yes. BioNixus designs and executes US HCP research in compliance with IRB/OHRP requirements under 45 CFR Part 46 (Common Rule) and HIPAA/HITECH data privacy standards. For studies requiring IRB review, BioNixus supports protocol development and ethics documentation. All US respondent recruitment is consent-based with documented data handling procedures.

How much does pharmaceutical market research cost in the USA?

Scope drives cost: a focused US physician quantitative survey often starts in the low-to-mid five figures USD; full mixed-method access programs with PBM payer mapping and KOL depth interviews are higher. BioNixus scopes programs to one decision per phase so sponsors avoid unfocused fieldwork spend. The US premium physician market requires verified HCP recruitment and IRB-compliant protocols, which reflects in project pricing.

Which US healthcare institutions does BioNixus recruit from?

BioNixus recruits from major US academic medical centres (Mayo Clinic, Cleveland Clinic, Johns Hopkins, UCSF Medical Center, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital), large hospital systems (HCA Healthcare, Ascension, CommonSpirit), and community practice networks across all US regions. For specialty areas such as oncology or rare disease, we extend recruitment to NCI-designated cancer centres and rare disease specialty networks.

Can US pharmaceutical research connect to wider global benchmarking?

Yes. US modules can run standalone or with comparable cells in the UK, Germany, France, Brazil, Saudi Arabia, or UAE using consistent instruments — enabling global portfolio committees to benchmark US market dynamics against international markets with one research partner.

Discuss your United States pharmaceutical research strategy

Our team supports pharmaceutical companies with decision-ready insights across MENA, UK, and Europe using quantitative and qualitative methodologies.

Request a proposal Email us

US No. +1 888 465 5557Europe No. +44 7727 666682Middle East, Africa and Asia No. +20 120 688 2323